STOCK TITAN

MapLight Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update

(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Tags

MapLight Therapeutics (Nasdaq: MPLT) reported a third-quarter net loss of $51.6 million while advancing its planned schizophrenia trial, ZEPHYR-2. The loss compared with $29.4 million a year earlier. Research and development expenses rose to $44.2 million from $27.1 million; general and administrative expenses increased to $11.1 million from $4.4 million.

Cash, cash equivalents and investments totaled $463.4 million at September 30, 2026, following an August $150 million private placement. MapLight expects funding to support ML-007C-MA through 2028. ZEPHYR-2 start-up activities have begun, with results expected in 2028; an FDA meeting is planned to discuss the registration path. Enrollment continues in the Phase 2 VISTA study in Alzheimer’s disease psychosis, with results expected in the second half of 2027. MapLight is pausing significant further investment in preclinical and discovery programs beyond near-term milestones.

Loading...
Loading translation...
16 points · 2 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

0 major · 11 points

Hollow bars mark forward-looking points. How the balance works

Positive

  • Major pointCompleted $150 million private placement primarily supports ML-007C-MA, including ZEPHYR-2 and VISTA. 37% of market cap
  • Major pointZEPHYR met its primary endpoint: 210/3 mg twice daily significantly reduced schizophrenia symptom scores versus placebo at Week 5.
  • Moderate point. Forward-looking: it has not happened yet and may not happen.Cash, cash equivalents and investments totaled $463.4 million; MapLight expects funding for ML-007C-MA through 2028.
  • Moderate point. Forward-looking: it has not happened yet and may not happen.ZEPHYR-2 start-up activities have begun; MapLight expects Phase 3 schizophrenia results in 2028.
  • Moderate pointZEPHYR secondary endpoints showed cognitive improvement in participants with baseline impairment and significant separation on other symptom measures.
  • Moderate point. Forward-looking: it has not happened yet and may not happen.VISTA enrollment continues in approximately 300 participants; MapLight expects Alzheimer’s disease psychosis results in the second half of 2027.
  • Moderate pointML-004 Phase 2 IRIS showed clinically meaningful improvement on a prespecified secondary irritability endpoint in adolescents with moderate-or-greater baseline irritability.
9 minor points
  • Minor pointZEPHYR tolerability included no serious or drug-related severe adverse events and low gastrointestinal-related discontinuation rates.
  • Minor pointFDA Fast Track designation was received in December 2025 for hallucinations and delusions associated with Alzheimer’s disease psychosis.
  • Minor pointML-004 tolerability included no severe or serious adverse events in the IRIS active treatment arm.
  • Minor pointThird-quarter basic and diluted loss per share narrowed to $0.97 from $37.18 a year earlier.
  • Minor pointNine-month basic and diluted loss per share narrowed to $3.60 from $105.70 a year earlier.
  • Minor pointThird-quarter interest income increased to $3.094 million from $1.549 million a year earlier.
  • Minor pointNine-month interest income increased to $7.915 million from $3.048 million a year earlier.
  • Minor pointThird-quarter other income, net, increased to $633,000 from $531,000 a year earlier.
  • Minor pointNine-month other income, net, increased to $3.004 million from $1.054 million a year earlier.

Negative

  • Moderate pointThird-quarter net loss widened to $51.6 million from $29.4 million a year earlier.
  • Moderate point. Forward-looking: it has not happened yet and may not happen.Preclinical and discovery investment is being paused beyond near-term milestones; clinical advancement is excluded under the current plan.
  • Minor pointNine-month net loss widened to $172.476 million from $81.604 million a year earlier.
  • Minor pointThird-quarter research and development expenses increased to $44.2 million from $27.1 million a year earlier.
  • Minor pointThird-quarter general and administrative expenses increased to $11.1 million from $4.4 million a year earlier.
6 minor points
  • Minor pointNine-month research and development expenses increased to $151.328 million from $73.726 million a year earlier.
  • Minor pointNine-month general and administrative expenses increased to $32.067 million from $11.980 million a year earlier.
  • Minor point. Forward-looking: it has not happened yet and may not happen.ML-007C-MA registration path remains subject to planned FDA discussion at an End-of-Phase 2 meeting.
  • Minor point. Forward-looking: it has not happened yet and may not happen.ML-004 development options await planned FDA discussion, followed by evaluation of potential collaborations or funding alternatives.
  • Minor pointTotal liabilities rose to $31.412 million at September 30, 2026, from $21.140 million at December 31, 2025.
  • Minor pointStockholders’ equity declined to $445.771 million at September 30, 2026, from $458.372 million at December 31, 2025.

News Explained

ML-004’s route remains open after an FDA discussion, while earlier-stage programs beyond near-term milestones are excluded from clinical advancement under the current plan.

For ML-004, MapLight plans an FDA End-of-Phase 2 meeting to discuss its potential registrational path, then plans to evaluate options including collaboration or funding alternatives, leaving the development route for later assessment. Under the current operating plan, MapLight is foregoing advancement of preclinical and discovery-stage programs beyond near-term milestones into clinical development.

Key Figures

Cash, cash equivalents and investments: $463.4 million Expected cash runway: Through 2028 R&D expenses: $44.2 million vs. $27.1 million +5 more
Cash, cash equivalents and investments
$463.4 million
As of September 30, 2026
Expected cash runway
Through 2028
Based on current operational plans and assumptions
R&D expenses
$44.2 million vs. $27.1 million
Third quarter 2026 vs. third quarter 2025
G&A expenses
$11.1 million vs. $4.4 million
Third quarter 2026 vs. third quarter 2025
Net loss
$51.6 million vs. $29.4 million
Third quarter 2026 vs. third quarter 2025
VISTA enrollment
Approximately 300 participants
Phase 2 Alzheimer’s disease psychosis trial
VISTA topline results
Expected in the second half of 2027
Phase 2 Alzheimer’s disease psychosis trial
ZEPHYR-2 topline results
Expected in 2028
Planned Phase 3 schizophrenia trial

Previous Earnings Reports

1 past event · Latest: Aug 13
Same Type 1 event
  1. Aug 13

    Q2 earnings

    24h Move
    +1.5%

    Reported positive ZEPHYR Phase 2 results, planned ZEPHYR-2, and expected funding through 2028.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

panss, fast track designation, double-blind, placebo-controlled, +1 more
5 terms
panss medical
"reduction in PANSS total score compared with placebo at Week 5"
A PANSS is a standardized clinical rating scale used in psychiatry to measure the severity of symptoms in disorders like schizophrenia, scoring both “positive” signs (added symptoms such as hallucinations or delusions) and “negative” signs (lost functions such as social withdrawal) plus general symptoms. Investors care because PANSS scores are a key way regulators and doctors judge whether a treatment meaningfully improves patients, so changes on this scale can determine a drug’s approval prospects, prescribing uptake, and commercial value — like a test score that helps predict market success.
fast track designation regulatory
"ML-007C-MA received Fast Track designation from the FDA"
Fast track designation is a status the U.S. Food and Drug Administration grants to drugs intended to treat serious conditions and address an unmet medical need. It gives the developer more frequent communication with the FDA and can allow parts of the application to be reviewed on a rolling basis, and it may pave the way to priority review or accelerated approval. It can shorten development timelines, though it does not guarantee approval.
double-blind medical
"a randomized, double-blind, placebo-controlled study"
A double-blind process means that neither the people conducting an activity nor the people involved know certain key details, such as who is receiving a treatment or a placebo. This approach helps prevent bias from influencing the results, making the outcome more trustworthy. For investors, it ensures that decisions or judgments are based on unbiased information rather than preconceived opinions or expectations.
placebo-controlled medical
"a randomized, double-blind, placebo-controlled study"
"Placebo-controlled" describes a testing method where one group receives the actual treatment or intervention, while another group receives a harmless, inactive version called a placebo. This approach helps determine whether the real treatment has genuine effects beyond psychological expectations. For investors, understanding this ensures confidence that reported benefits are real and not influenced by bias or false perceptions.
muscarinic agonist medical
"ML-007C-MA (M1/M4 Muscarinic Agonist)"
A muscarinic agonist is a drug that activates muscarinic acetylcholine receptors, the molecular 'switches' on cells that help control functions like heart rate, digestion, breathing and certain brain activities. Investors care because these drugs can become treatments for conditions such as dry mouth, glaucoma, Alzheimer's symptoms or bladder problems, and their safety, regulatory approval and market potential directly affect a company’s revenue prospects and risk profile.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

Planning underway for ZEPHYR-2, the confirmatory Phase 3 trial of ML-007C-MA in schizophrenia, with topline results expected in 2028

Enrollment ongoing in Phase 2 VISTA trial in Alzheimer’s disease psychosis, with topline results expected in the second half of 2027; ML-007C-MA holds FDA Fast Track designation in ADP

Ended the quarter with $463.4 million in cash, cash equivalents and investments, expected to fund operations through key clinical readouts and through 2028

SAN FRANCISCO and BOSTON, Nov. 16, 2026 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc. (Nasdaq: MPLT), a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system disorders, today reported financial results for the third quarter ended September 30, 2026, and provided a business update.

“Following the positive results from our ZEPHYR study, we are focused on advancing ML-007C-MA into an additional registrational study and positioning it to compete in the broader antipsychotic market,” said Chris Kroeger, Co-Founder and Chief Executive Officer of MapLight. “We believe that the strength and consistency of the ZEPHYR efficacy results, combined with the ease-of-use tolerability profile, provide a solid foundation for our planned Phase 3 trial and reinforce our confidence in the potential of ML-007C-MA in schizophrenia.”

“We also see a compelling opportunity for ML-007C-MA in Alzheimer’s disease psychosis, where its clinical profile offers the potential for meaningful differentiation. With our cash position expected to fund operations through 2028, we are well-positioned to advance both programs while maintaining strategic and financial flexibility.”

Business Update and Upcoming Milestones

ML-007C-MA (M1/M4 Muscarinic Agonist) for the Treatment of Schizophrenia

  • The Company has initiated start-up activities for ZEPHYR-2, its planned Phase 3 trial, and intends to engage with the FDA at an End-of-Phase 2 meeting to discuss the registrational path forward, with topline results expected in 2028.
  • As previously reported in July 2026, the Phase 2 ZEPHYR trial of ML-007C-MA in adults with schizophrenia experiencing an acute exacerbation of psychosis met its primary endpoint, with the 210/3 mg twice-daily dose demonstrating a statistically significant and clinically meaningful reduction in PANSS total score compared with placebo at Week 5.
  • ML-007C-MA also demonstrated improvement on a prespecified cognitive-function endpoint in participants with baseline cognitive impairment and significant separation on key secondary endpoints, including CGI-S and the PANSS Marder positive factor.
  • ML-007C-MA was generally well tolerated, with no serious or drug-related severe adverse events and low rates of GI-related discontinuations. Its clinical profile – characterized by simple initiation, 99% of patients reaching the target dose, and no fasting requirement – is designed to translate into real-world use.

ML-007C-MA for the Treatment of Alzheimer’s Disease Psychosis (ADP)

  • Enrollment continues in the Phase 2 VISTA trial, a randomized, double-blind, placebo-controlled study evaluating ML-007C-MA in approximately 300 participants with ADP.
  • ML-007C-MA received Fast Track designation from the FDA in December 2025 for the treatment of hallucinations and delusions associated with ADP.
  • Topline results from VISTA are expected in the second half of 2027.

ML-004 (5-HT1B/1D Agonist) for the Treatment of Autism Spectrum Disorder (ASD)

  • The Company plans to engage with the FDA at an End-of-Phase 2 meeting to discuss the potential registrational path forward for ML-004. Following this discussion, the Company intends to evaluate development options, including potential strategic collaborations and/or funding alternatives.
  • As previously reported in June 2026, the Phase 2 IRIS trial of ML-004 in autism spectrum disorder demonstrated clinically meaningful improvements in a pre-specified secondary irritability endpoint among adolescents with moderate or greater baseline irritability.
  • ML-004 was generally well tolerated in the IRIS trial, with no severe or serious adverse events in the active treatment arm. This profile is relevant in a treatment setting with limited approved options, where antipsychotic-associated safety and tolerability concerns can present challenges for long-term use, particularly in younger patients.

Corporate Updates

  • As previously announced in August 2026, the Company completed a $150 million private placement with participation from new and existing institutional investors. Proceeds from the financing are expected to primarily support the continued advancement of ML-007C-MA, including the planned ZEPHYR-2 trial and ongoing VISTA trial, as well as working capital and other general corporate purposes.
  • The Company continues to focus resources on the advancement of ML-007C-MA, including pausing significant further investment in preclinical and discovery-stage programs beyond near-term milestones and foregoing advancement of those programs into clinical development under the current operating plan.

Third Quarter 2026 Financial Results

  • Cash Position: Cash, cash equivalents and investments were $463.4 million as of September 30, 2026. Based on current operational plans and assumptions, the Company expects that its existing cash, cash equivalents and investments will be sufficient to fund the continued advancement of ML-007C-MA through 2028.
  • R&D Expenses: Research and development (R&D) expenses were $44.2 million for the third quarter of 2026, as compared to $27.1 million for the third quarter of 2025. R&D expenses increased primarily due to the ongoing advancement of the Company’s product candidates and increases in employee-related expenses, including an increase in stock-based compensation expense of $5.8 million.
  • G&A Expenses: General and administrative (G&A) expenses were $11.1 million for the third quarter of 2026, as compared to $4.4 million for the third quarter of 2025. G&A expenses increased primarily due to increases in employee-related expenses, including an increase in stock-based compensation expense of $4.3 million, and increases in professional fees and other expenses.
  • Net Loss: Net loss was $51.6 million for the third quarter of 2026, as compared to $29.4 million for the third quarter of 2025.

About MapLight Therapeutics

MapLight Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system disorders. The Company was founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. The Company’s discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation.

For more information, please visit www.maplightrx.com.

Forward-Looking Statements

Certain statements in this press release may constitute “forward-looking statements” within the meaning of the federal securities laws, including, but not limited to, the clinical development and potential benefits of ML-007C-MA and ML-004, the design, timing and conducting of future clinical trials, the registrational pathway for the Company’s product candidates, including holding End-of-Phase 2 meetings with the FDA for ML-007C-MA and ML-004 and planned regulatory submissions, the availability and timing of results from the Company’s VISTA and ZEPHYR-2 trials, the use of proceeds from the Company’s August 2026 private placement, the sufficiency of the Company’s cash, cash equivalents and investments to fund its operations through 2028. Words such as “may,” “might,” “will,” “objective,” “intend,” “should,” “could,” “can,” “would,” “expect,” “believe,” “design,” “estimate,” “predict,” “potential,” “develop,” “plan” or the negative of these terms, and similar expressions, are intended to identify forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to the Company on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties (including, without limitation, those set forth in the Company’s filings with the U.S. Securities and Exchange Commission (SEC)), many of which are beyond the Company’s control and subject to change. Actual results could be materially different. Risks and uncertainties include: the unpredictable relationship between preclinical study results and clinical study results; the risk that results obtained in any clinical trials to date may not be indicative of results obtained in ongoing or future trials; the timing or likelihood of regulatory filings and approvals; expectations regarding the Company’s ability to fund its current operations; and other risks and uncertainties identified in the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2026, and subsequent disclosure documents the Company may file with the SEC. The Company claims the protection of the safe harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. The Company expressly disclaims any obligation to update or alter any statements whether as a result of new information, future events or otherwise, except as required by law.

     
MapLight Therapeutics, Inc.

Condensed Consolidated Statements of Operations
(Unaudited)

(in thousands, except share and per share amounts)
     
  Three Months Ended September 30, Nine Months Ended September 30,
   2026   2025   2026   2025 
Operating expenses:        
Research and development $44,208  $27,094  $151,328  $73,726 
General and administrative  11,135   4,404   32,067   11,980 
Total operating expenses  55,343   31,498   183,395   85,706 
Loss from operations  (55,343)  (31,498)  (183,395)  (85,706)
Other income, net:        
Interest income  3,094   1,549   7,915   3,048 
Other income, net  633   531   3,004   1,054 
Net loss $(51,616) $(29,418) $(172,476) $(81,604)
Net loss per share - basic and diluted $(0.97) $(37.18) $(3.60) $(105.70)
Weighted-average number of common shares outstanding - basic and diluted  53,100,322   791,127   47,964,806   772,031 
         
         
      September 30, December 31,
       2026   2025 
Cash, cash equivalents and investments     $463,413  $453,096 
Total assets      477,183   479,512 
Total current liabilities      30,902   16,229 
Total liabilities      31,412   21,140 
Total stockholders' equity      445,771   458,372 



For investor inquiries: investors@maplightrx.com
For media inquiries: media@maplightrx.com


FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How much cash does MapLight Therapeutics have and how long is it expected to last?

MapLight held $463.4 million in cash, cash equivalents and investments at September 30, 2026. Based on current operational plans and assumptions, the company expects those resources to fund continued advancement of ML-007C-MA through 2028.

When does MapLight expect ZEPHYR-2 and VISTA trial results?

MapLight expects ZEPHYR-2 results in 2028 and VISTA results in the second half of 2027. Start-up activities have begun for the planned Phase 3 schizophrenia trial, while enrollment continues in the Phase 2 Alzheimer’s disease psychosis trial.

What did MapLight’s Phase 2 ZEPHYR schizophrenia trial show?

ZEPHYR met its primary endpoint: 210/3 mg twice daily significantly reduced total scores on the Positive and Negative Syndrome Scale, a schizophrenia symptom measure, versus placebo at Week 5. Cognitive improvement was also observed in participants with baseline cognitive impairment. No serious or drug-related severe adverse events were reported.

What are MapLight’s next steps for ML-004 in autism spectrum disorder?

MapLight plans an End-of-Phase 2 FDA meeting to discuss a potential registration path for ML-004. After that discussion, the company intends to evaluate development options, including potential collaborations or funding alternatives. The Phase 2 IRIS trial showed improvement on a prespecified secondary irritability endpoint among adolescents with moderate or greater baseline irritability.

Why did MapLight’s third-quarter 2026 operating expenses increase?

Research and development expenses increased primarily because of product-candidate advancement and employee-related expenses, while administrative expenses rose primarily because of employee costs, professional fees and other expenses. The employee-cost increases included $5.8 million more stock-based compensation in research and development and $4.3 million more in general and administrative expenses.

Keep reading